Комбінація в одній таблетці периндоприлу, індапаміду та амлодипіну в пацієнтів з артеріальною гіпертензією та ожирінням: тривала ефективність
Rattachement africain : ua. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Treatment of patients with arterial hypertension associated with abdominal obesity (AO) is complex and most often requires the use of several antihypertensive agents. Achieving target of blood pressure (BP) is most difficult in cases of association of hypertension with a number of metabolic diseases, the most common of which is AO. When hypertension is combined with AO, there is a more rapid and pronounced development of such pathological changes as activation of the renin-angiotensin-aldosterone system, atherogenic dyslipidemia, insulin resistance, hypeuricemia and subclinical inflammation. Objective — to evaluate the advantages of the single-pill combination (SPC) of perindopril, indapamide and amlodipine in comparison with their free combination (FC) in achieving effective control of hypertension for a long time in patients with AO. Materials and methods. 75 patients (of which 45 men) with uncontrolled hypertension associated with AO (age 48 — 66 years old) were examined. Among patients included in the study, 36 received a FC of perindopril, indapamide and amlodipine, and 39 — SPC of these drugs. The drugs were used once a day in the following daily doses: perindopril — 4 — 8 mg, indapamide — 1.25 — 2.5 mg and amlodipine — 5 — 10 mg. Patients were followed up for 12 months. Results. SPC of perindopril, indapamide and amlodipine were significantly more effective than FC in hypertensive patients with АO. The high efficiency of SPC persisted for a long time (over the course of 12 months) and associated with significantly increased adherence to therapy in comparison with FC. To achieve target BP levels with SPC, lower doses of drugs were required than with FC. Conclusions. SPC of P, I and A shows greater efficiency than FC, and makes it possible to maintain BP within the target levels for a long time with lower doses of drugs. The high efficiency of SPC associated with significantly increased adherence to therapy in comparison with FC. To achieve target BP levels with SPC, lower doses of drugs were required than with FC. SPC and FC in patients with hypertension and AO contributed to the inhibition of asymptomatic hypertension-mediated organ damage progression, did not adversely affect metabolic parameters, and were characterized by high safety.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
Où se fait cette recherche
-
L.T. Malaya National Therapy Institute of the National Academy of Medical Sciences of Ukraine pays non établi dans la noticeOrganisme public
-
Ministry of Health Ukrainian Scientific and Practical Center of Endocrine Surgery pays non établi dans la noticeOrganisme public
-
National University of Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
Zaporizhzhya Institute of Economics and Information Technologies pays non établi dans la noticeUniversité ou école supérieure
-
Zaporizhzhia National University pays non établi dans la noticeUniversité ou école supérieure
-
GI «L. T. Mala National Therapy Institute of NAMS of Ukraine» pays non établi dans la noticeStructure de recherche
-
Military Medical Clinical Center of the North Region of the Medical Forces Command pays non établi dans la noticeÉtablissement de santé
-
Clinic Vitacenter pays non établi dans la noticeÉtablissement de santé
L.T. Malaya National Therapy Institute of the National Academy of Medical Sciences of Ukraine, Ukrainian Scientific and Practical Center of Endocrine Surgery — Ministry of Health et National University of Pharmacy, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.